March 15, 2025

Bolt Biotherapeutics

Investors

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bolt

NEW YORK, Aug. 17, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the “Class Period”), of the important September 3, 2024 lead plaintiff deadline. SO WHAT: If you

Read More
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline